Nadia Withofs1, Philippe Martinive2, Jean Vanderick2, Noëlla Bletard3, Irène Scagnol3, Frédéric Mievis4, Fabrice Giacomelli4, Philippe Coucke2, Philippe Delvenne3, Didier Cataldo5, Sanjiv S Gambhir6, Roland Hustinx7. 1. Department of Medical Physics, Division of Nuclear Medicine and Oncological Imaging, B35 Domaine universitaire du Sart Tilman, 4000, Liege, Belgium. 2. Division of Radiation Oncology, Department of Medical Physics, CHU Liège, Liège, Belgium. 3. Department of Pathology, CHU Liège, Liège, Belgium. 4. CYCLOTRON Research Centre, University of Liège, Liège, Belgium. 5. Laboratory of Tumour and Developmental Biology, GIGA-Research, University of Liège, Liège, Belgium. 6. Molecular Imaging Program at Stanford (MIPS), Radiology Department, Stanford University, Stanford, CA, USA. 7. Department of Medical Physics, Division of Nuclear Medicine and Oncological Imaging, B35 Domaine universitaire du Sart Tilman, 4000, Liege, Belgium. rhustinx@chu.ulg.ac.be.
Abstract
PURPOSE: Our primary objective was to determine if [(18)F]FPRGD2 PET/CT performed at baseline and/or after chemoradiotherapy (CRT) could predict tumour regression grade (TRG) in locally advanced rectal cancer (LARC). Secondary objectives were to compare baseline [(18)F]FPRGD2 and [(18)F]FDG uptake, to evaluate the correlation between posttreatment [(18)F]FPRGD2 uptake and tumour microvessel density (MVD) and to determine if [(18)F]FPRGD2 and FDG PET/CT could predict disease-free survival. METHODS: Baseline [(18)F]FPRGD2 and FDG PET/CT were performed in 32 consecutive patients (23 men, 9 women; mean age 63 ± 8 years) with LARC before starting any therapy. A posttreatment [(18)F]FPRGD2 PET/CT scan was performed in 24 patients after the end of CRT (median interval 7 weeks, range 3 - 15 weeks) and before surgery (median interval 4 days, range 1 - 15 days). RESULTS: All LARC showed uptake of both [(18)F]FPRGD2 (SUVmax 5.4 ± 1.5, range 2.7 - 9) and FDG (SUVmax 16.5 ± 8, range 7.1 - 36.5). There was a moderate positive correlation between [(18)F]FPRGD2 and FDG SUVmax (Pearson's r = 0.49, p = 0.0026). There was a moderate negative correlation between baseline [(18)F]FPRGD2 SUVmax and the TRG (Spearman's r = -0.37, p = 0.037), and a [(18)F]FPRGD2 SUVmax of >5.6 identified all patients with a complete response (TRG 0; AUC 0.84, 95 % CI 0.68 - 1, p = 0.029). In the 24 patients who underwent a posttreatment [(18)F]FPRGD2 PET/CT scan the response index, calculated as [(SUVmax1 - SUVmax2)/SUVmax1] × 100 %, was not associated with TRG. Post-treatment [(18)F]FPRGD2 uptake was not correlated with tumour MVD. Neither [(18)F]FPRGD2 nor FDG uptake predicted disease-free survival. CONCLUSION: Baseline [(18)F]FPRGD2 uptake was correlated with the pathological response in patients with LARC treated with CRT. However, the specificity was too low to consider its clinical routine use.
PURPOSE: Our primary objective was to determine if [(18)F]FPRGD2 PET/CT performed at baseline and/or after chemoradiotherapy (CRT) could predict tumour regression grade (TRG) in locally advanced rectal cancer (LARC). Secondary objectives were to compare baseline [(18)F]FPRGD2 and [(18)F]FDG uptake, to evaluate the correlation between posttreatment [(18)F]FPRGD2 uptake and tumour microvessel density (MVD) and to determine if [(18)F]FPRGD2 and FDG PET/CT could predict disease-free survival. METHODS: Baseline [(18)F]FPRGD2 and FDG PET/CT were performed in 32 consecutive patients (23 men, 9 women; mean age 63 ± 8 years) with LARC before starting any therapy. A posttreatment [(18)F]FPRGD2 PET/CT scan was performed in 24 patients after the end of CRT (median interval 7 weeks, range 3 - 15 weeks) and before surgery (median interval 4 days, range 1 - 15 days). RESULTS: All LARC showed uptake of both [(18)F]FPRGD2 (SUVmax 5.4 ± 1.5, range 2.7 - 9) and FDG (SUVmax 16.5 ± 8, range 7.1 - 36.5). There was a moderate positive correlation between [(18)F]FPRGD2 and FDG SUVmax (Pearson's r = 0.49, p = 0.0026). There was a moderate negative correlation between baseline [(18)F]FPRGD2 SUVmax and the TRG (Spearman's r = -0.37, p = 0.037), and a [(18)F]FPRGD2 SUVmax of >5.6 identified all patients with a complete response (TRG 0; AUC 0.84, 95 % CI 0.68 - 1, p = 0.029). In the 24 patients who underwent a posttreatment [(18)F]FPRGD2 PET/CT scan the response index, calculated as [(SUVmax1 - SUVmax2)/SUVmax1] × 100 %, was not associated with TRG. Post-treatment [(18)F]FPRGD2 uptake was not correlated with tumour MVD. Neither [(18)F]FPRGD2 nor FDG uptake predicted disease-free survival. CONCLUSION: Baseline [(18)F]FPRGD2 uptake was correlated with the pathological response in patients with LARC treated with CRT. However, the specificity was too low to consider its clinical routine use.
Entities:
Keywords:
Angiogenesis; Integrin; PET; RGD; Rectal cancer
Authors: E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde Journal: N Engl J Med Date: 2001-08-30 Impact factor: 91.245
Authors: Nadia Withofs; Nicolas Signolle; Joan Somja; Pierre Lovinfosse; Eugène Mutijima Nzaramba; Frédéric Mievis; Fabrice Giacomelli; David Waltregny; Didier Cataldo; Sanjiv S Gambhir; Roland Hustinx Journal: J Nucl Med Date: 2015-02-05 Impact factor: 10.057
Authors: E Élez; I Kocáková; T Höhler; U M Martens; C Bokemeyer; E Van Cutsem; B Melichar; M Smakal; T Csőszi; E Topuzov; R Orlova; S Tjulandin; F Rivera; J Straub; R Bruns; S Quaratino; J Tabernero Journal: Ann Oncol Date: 2014-10-15 Impact factor: 32.976
Authors: Nadia Withofs; François Cousin; Bernard De Prijck; Christophe Bonnet; Roland Hustinx; Sanjiv S Gambhir; Yves Beguin; Jo Caers Journal: Contrast Media Mol Imaging Date: 2017-07-27 Impact factor: 3.161